

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Result of the public tender offer to the shareholders of ViroGates A/S

12 November 2025

Reference is made to the announcements published by ViroGates A/S (**ViroGates** or the **Company**) on 8 October 2025 and on 10 October 2025 concerning suPAR Remedy, LLC's (the **Offeror**) public tender offer to the shareholders of ViroGates (the **Tender Offer**). The offer period began on 10 October 2025 and expired on 7 November 2025 at 11:59 p.m. (CET) in accordance with the terms of the Tender Offer as set out in the offer document published by the Offeror on 10 October 2025 (the **Offer Document**). The Offeror hereby announces the result of the Tender Offer.

Result and completion of the Tender Offer

The Offeror has received acceptances from shareholders tendering their shares in the Tender Offer representing 487,975 shares in ViroGates, corresponding to approximately 6.31 per cent of the entire share capital and voting rights in ViroGates.

The Offeror considers all conditions to completion pursuant to the Tender Offer satisfied and consequently, the Tender Offer is concluded and will be completed on the terms set forth in the Offer Document.

On that basis, the Offeror will upon completion of the Tender Offer hold 2,671,299 shares in ViroGates, corresponding to approximately 34.54 per cent of the share capital and voting rights in ViroGates, excluding the 2,585 treasury shares held by ViroGates at the date hereof.

"This Tender Offer should reflect my confidence in the science of suPAR (soluble urokinase Plasminogen Activator Receptor) and its potential as the biomarker for chronic inflammation, on a global stage. As an aspiring medical anthropologist, I spent an enjoyable summer in Denmark collaborating with the Virogates family, hearing stories from their 25 year operating history, and sharing insights from my experience preparing for distribution of suPAR in the United States - a country where roughly 75% of the healthcare costs are for conditions caused by chronic inflammation.

Our shared mission is to make suPAR a household name - similar to biomarker's like cholesterol, insulin, and glucose. By bringing awareness, we tap into human curiosity and create a bridge between scientific discovery and personal empowerment. I believe that when an individual learns about suPAR, they may seek to understand themselves further through a blood test which reveals their levels of chronic inflammation in the body." said **Matt Wiggins, Managing Partner of the Offeror**.

Settlement of the Tender Offer

The Tender Offer will be settled in accordance with the terms and conditions of the Offer Document by payment of the offer price to each shareholder whose shares have been accepted for purchase under the Tender Offer.

The full terms, conditions and essential elements, including settlement, of the Tender Offer are set forth in the Offer Document, which can, subject to certain restrictions, be viewed and downloaded at <https://www.virogates.com/public-tender-offer-2025/>.

The Offeror reserves the right to acquire shares in ViroGates, regardless of the expiry of the offer period, in public trading on Nasdaq First North Growth Market or otherwise.

Advisers

Kromann Reumert is acting as legal adviser to the Offeror in connection with the Tender Offer. Nordea Danmark, Filial af Nordea Bank Abp, Finland is acting as settlement agent to the Offeror in connection with the Tender Offer.

About the Offeror

The Offeror is an investment vehicle formed for the purpose of holding shares in ViroGates. In October 2024, ViroGates and suPAR Health LLC signed an exclusive US distribution agreement for certain of ViroGates' proprietary products. Both suPAR Health LLC and the Offeror are wholly owned subsidiaries of Remedy Ventures 2, LLC, a venture studio and investment vehicle based in the United States managed by a team of seasoned United States healthcare entrepreneurs. Remedy Venture 2, LLC, is 100% owned by Matt Wiggins, who is also Managing Partner of the Offeror.

The products enable testing for soluble urokinase plasminogen activator receptor (suPAR), a biomarker for chronic inflammation. Since then, suPAR Health LLC has been actively exploring strategies to launch suPAR blood tests in the United States. The mission of suPAR Health LLC is to make suPAR a recognized biomarker across the United States, betting on widespread adoption through awareness campaigns targeted at clinicians and individuals alike. To achieve this, suPAR Health LLC is working to:

1. Comply with state-by-state regulations for diagnostic testing, while ensuring the highest standards of safety and effectiveness.
2. Expand market opportunities in the burgeoning field of chronic inflammation diagnostics, which is gaining traction as a key area of clinical and personal health management.

Disclaimers

This announcement does not constitute an offer or invitation to purchase any securities in ViroGates or a solicitation of an offer to buy any securities in ViroGates, pursuant to the voluntary Tender Offer by suPAR Remedy, LLC or otherwise. The Tender Offer has been made solely by means of the Offer Document, which contain the full terms and conditions of the Tender Offer, including details of how the Tender Offer could be accepted.

Important information

This announcement is not directed at ViroGates shareholders whose participation in the Tender Offer would require issuance of an offer document, registration or any activities. The Tender Offer is not being made, and the shares will not be accepted for purchase from or on behalf of persons, in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws or regulations of such jurisdiction, including sanction laws, or would require any registration, approval or filing with any regulatory authority. Persons obtaining this announcement and/or into whose possession this announcement or any other document referring to the Tender Offer comes are required to take due note and observe all such restrictions and obtain any necessary authorizations, approvals or consents.

Neither ViroGates, the Offeror, any of their advisors nor the settlement bank accepts any liability for any violation by any person of any such restriction. Any person (including, without limitation custodians, nominees and trustees) who intends to forward this announcement or documents related to the Tender Offer to any jurisdiction outside Denmark should inform themselves of the laws of the relevant jurisdiction. The distribution of this announcement in jurisdictions other than Denmark may be restricted by law, and, therefore, persons who come into possession of this announcement should inform themselves

about and observe such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws and regulations of any such jurisdiction.

Forward looking statements

This announcement contains certain statements about ViroGates and its business as well as the timing and procedures relating to the Tender Offer and potential amendments to the Tender Offer that are or may be forward-looking statements. Forward-looking statements are typically identified by the use of forward-looking terminology such as "believes", "expects", "may", "will", "could", "should", "intends", "estimates", "plans", "assumes" or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond ViroGates and the Offeror's control and all of which are based on ViroGates and the Offeror's current beliefs and expectations about future events. In addition, from time to time, ViroGates, the Offeror or their representatives have made or may make forward-looking statements orally or in writing. Such forward-looking statements may be included in, but are not limited to, press releases or oral statements made by or with the approval of ViroGates or the Offeror's authorised executive officers. By their nature, forward-looking statements involve risks and uncertainties beyond ViroGates' and the Offeror's control because they relate to future events and circumstances. As a result, actual future results may differ materially from the plans, goals, and expectations set forth in these forward-looking statements. Any forward-looking statements made herein speak only as of the date they are made. ViroGates and the Offeror disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in ViroGates' and the Offeror's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.